Nagraj Mani

机构：Sage Therapeutics (United States), Io Therapeutics (United States) · ORCID：0000-0002-8446-2338

发表论文 60 篇 · 总被引 2139 次 · h-index 22

代表论文

• Targeting the multifunctional HBV core protein as a potential cure for chronic hepatitis B (2020 · Antiviral Research · 被引 98)
• Nomenclature of HBV core protein-targeting antivirals (2022 · Nature Reviews Gastroenterology & Hepatology · 被引 66)
• Preclinical Profile of AB-423, an Inhibitor of Hepatitis B Virus Pregenomic RNA Encapsidation (2018 · Antimicrobial Agents and Chemotherapy · 被引 59)
• Inhibition of HBV replication by N-hydroxyisoquinolinedione and N-hydroxypyridinedione ribonuclease H inhibitors (2019 · Antiviral Research · 被引 38)
• Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB‐506 from Phase 1 studies in healthy subjects and those with hepatitis B (2022 · Hepatology Communications · 被引 27)
• Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein (2021 · Antiviral Research · 被引 20)